“Lines of therapy” is a counting system doctors use for drug treatment: the first planned drug approach for a given situation is the first line, and if that approach is changed — because it stops working or is not tolerated — the next one becomes the second line, and so on. The term is used mainly for systemic (whole-body) drug therapy, most often when breast cancer has spread or come back. Understanding what a “line” means can make conversations about your plan, and paperwork that uses the phrase, much easier to follow.
Key Takeaways
- A “line” is one planned drug-treatment approach. First-line is the first; second-line is the next distinct approach, not a stronger version of the same one.
- Moving to a new line usually means the previous approach stopped working or its side effects were not manageable — it is a normal part of long-term treatment planning, not a failure by you.
- Lines are counted for drug therapy (chemotherapy, hormone therapy, targeted therapy, immunotherapy). Surgery and radiation are not usually counted as lines.
- What counts as first-line depends on the situation — the cancer’s receptor and HER2 results, where it has spread, and what treatment you have already had.
- Each new line is a fresh decision your team makes with you, weighing benefit, side effects, and your priorities.
What a “Line” Actually Means
Think of a line of therapy as a chapter of drug treatment. When a team starts a drug approach for a particular situation — say, the first treatment for cancer that has spread to other parts of the body — that is chapter one: the first line. The approach may involve a single medicine or a combination given together; a combination used as one plan still counts as one line. If that plan is later replaced by a different drug approach, the replacement is the second line. A third distinct approach becomes the third line.
The phrase appears everywhere once you start listening for it: clinic letters, scan reports, insurance paperwork, and clinical trial descriptions, which often specify that they are open to people who have had a certain number of prior lines. Our pillar guide to how breast cancer treatment plans are made shows how drug treatment sits within the whole plan, and our guide to treatment goals by stage explains how the purpose of drug treatment shifts between early-stage and advanced disease — which is also where line-counting becomes most relevant.
When and Why a Line Changes
A line changes when the plan changes, and plans change for a few ordinary reasons:
- The treatment stops controlling the cancer. Scans or symptoms show the cancer growing despite treatment. This is the most common reason for moving to the next line.
- Side effects become too much. A treatment that works but cannot be tolerated may be swapped for another approach, and that swap starts a new line.
- The situation changes. New information — for example, results from a fresh biopsy of a recurrence — can point the team toward a different kind of drug treatment.
What does not count as a new line: a dose adjustment, a pause in treatment, or swapping one supportive medicine for another. And an important emotional point: moving lines is not something you caused. Cancers adapt, and treatment plans are designed with the expectation that adaptation may be needed — particularly in advanced disease, where a sequence of lines over time is the standard shape of care. Our article on treatment for recurrent breast cancer describes how plans are rebuilt when cancer returns, which is often when line-counting begins.
What Counts as a Line — and What Does Not
| Situation | Usually counted as a line? | Why |
|---|---|---|
| First drug approach for cancer that has spread | Yes — first line | It is the first systemic plan for that situation |
| A different drug approach after the first stops working | Yes — second line | A new plan replaces the old one |
| A combination of drugs given together as one plan | One line | The combination is a single approach |
| Dose lowered, or treatment paused and restarted | No | The plan is the same, adjusted |
| Surgery or radiation to one area | No | Lines count drug therapy, not local treatments |
| Drug treatment after surgery for early-stage cancer (adjuvant) | Usually described separately | “Lines” language is used mainly for advanced or recurrent disease |
Counting conventions can differ slightly between teams and documents, so if a letter or a trial description counts your lines differently from how you understood them, ask your team to walk through the count with you. The number matters in practical ways — some clinical trials and some drug approvals are framed around how many lines a person has already had.
How the First Line Is Chosen
There is no universal first line; there is a first line for your situation. The main ingredients are the cancer’s biology — its hormone receptor and HER2 results, which point toward hormone therapy, HER2-targeted therapy, chemotherapy, or immunotherapy in different combinations — where the cancer has spread, how quickly it appears to be changing, what treatment you have had before, and your overall health. A treatment you already received for early-stage disease can influence the choice, because a cancer that returned during or soon after a particular drug is less likely to be offered the same drug again.
Your preferences are an ingredient too: how treatment is given, how often it involves hospital visits, and which side effects you most want to avoid are legitimate parts of the discussion. If you want to understand the reasoning, “What makes this the right first line for me, and what would we hold in reserve?” is a good question to ask out loud.
What Later Lines Involve
Later lines draw on the same families of drug treatment, sequenced differently. A second or later line may be a different chemotherapy, a hormone-based approach not used before, a targeted drug matched to a feature of the cancer, or a clinical trial of a newer approach. Genetic testing of the tumour — and sometimes inherited-gene testing — can widen the options by revealing features that specific drugs are designed to address, which is why testing may be repeated or extended when the plan is being rebuilt.
As lines progress, the balance of the conversation often shifts toward quality of life alongside cancer control: how you feel on treatment matters as much as what scans show, and your team relies on you to report the day-to-day reality. It is also common to revisit goals at each change of line — what this treatment is for, what would count as it helping, and when you would reconsider. Individual situations differ enormously, so treat this article as a map of the vocabulary and talk through your own sequence with your doctor and care team. The National Cancer Institute at cancer.gov and the American Cancer Society at cancer.org publish current general information about treatment approaches for advanced breast cancer.
Questions to Ask Your Doctor
- Which line of therapy am I on now, and how is the count being made in my case?
- What is this line intended to do — control the cancer, relieve symptoms, or both?
- What would make us decide this line has stopped working, and how will we know?
- If this line stops working, what are the likely next options?
- Would a clinical trial be an option at any point in my sequence?
- Has my tumour been tested for features that could open up other drug options later?
Frequently Asked Questions
Does needing a second line mean my treatment failed?
No. It means the first approach did what it could for as long as it could, and the plan is moving to its next step. In advanced breast cancer, a sequence of lines is the expected pattern of care — each line is chosen because it offers a further chance of control.
Is second-line treatment stronger than first-line?
Not necessarily. “Line” describes order, not strength. A later line is a different approach, chosen for your situation at that point; some later-line treatments are gentler than the first, and some are more intensive. Your team can explain what to expect from the specific plan proposed.
How many lines of therapy are there?
There is no fixed number. It depends on the cancer’s biology, how each treatment performs, your health, and what you want from treatment. Some people have several lines over a long period; others have fewer. Your team can talk honestly about the outlook in your own case.
Does adjuvant chemotherapy count as a first line?
Usually the counting restarts in a new situation: drug treatment given after surgery for early-stage cancer is described as adjuvant treatment, and “first line” typically refers to the first drug approach for advanced or recurrent disease. Conventions vary, so ask your team how they are counting yours.
Why do clinical trials mention lines of therapy?
Trials are designed for defined groups, and prior treatment is one of the things that defines a group. A trial may be open to people who have not yet had drug treatment for advanced disease, or specifically to people who have had one or more lines. Your team can check which trials fit your position in the sequence.
Related Articles
- How Breast Cancer Treatment Plans Are Made: A Plain-Language Guide
- How Treatment Goals Change by Stage, in Plain Language
- When Breast Cancer Comes Back: General Approaches to Treating a Recurrence
- Metastatic vs Recurrent Breast Cancer
- Stage 3 Breast Cancer Treatment: General Approaches Explained
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.